董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Louis Lange | 男 | Director | 76 | 未披露 | 未持股 | 2024-10-28 |
| Michael Davidson | 男 | Chief Executive Officer, Director | 67 | 未披露 | 未持股 | 2024-10-28 |
| Michael Davidson | 男 | Chief Executive Officer, Director | 66 | 未披露 | 未持股 | 2024-10-28 |
| John Kastelein | 男 | Chief Scientific Officer and Director | 69 | 未披露 | 未持股 | 2024-10-28 |
| Juliette Audet | 女 | Vice Chairperson, Director | 37 | 未披露 | 未持股 | 2024-10-28 |
| Sander Slootweg | 男 | Chairperson, Director | 54 | 未披露 | 未持股 | 2024-10-28 |
| Nicholas Downing | 男 | Director | 37 | 未披露 | 未持股 | 2024-10-28 |
| John W. Smither | 男 | Temporary Director | 70 | 未披露 | 未持股 | 2024-10-28 |
| Janneke van der Kamp | 女 | Temporary Director | 48 | 未披露 | 未持股 | 2024-10-28 |
| James N. Topper | 男 | Director | 62 | 未披露 | 未持股 | 2024-10-28 |
| Sander Slootweg | 男 | Chairperson, Director | 55 | 未披露 | 未持股 | 2024-10-28 |
| John W. Smither | 男 | Temporary Director | 70 | 未披露 | 未持股 | 2024-10-28 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Davidson | 男 | Chief Executive Officer, Director | 67 | 未披露 | 未持股 | 2024-10-28 |
| Michael Davidson | 男 | Chief Executive Officer, Director | 66 | 未披露 | 未持股 | 2024-10-28 |
| John Kastelein | 男 | Chief Scientific Officer and Director | 69 | 未披露 | 未持股 | 2024-10-28 |
| Marc Ditmarsch | 男 | Chief Development Officer | 57 | 未披露 | 未持股 | 2024-10-28 |
| Douglas Kling | 男 | Chief Operating Officer | 49 | 未披露 | 未持股 | 2024-10-28 |
| Louise Kooij | 女 | Interim Chief Financial Officer | 47 | 未披露 | 未持股 | 2024-10-28 |
董事简历
中英对照 | 中文 | 英文- Louis Lange
-
Louis Lange，医学博士，自2022年9月起担任Epiphany Technology Acquisition Corp.的董事之一，作为生物技术领域领先的企业家、投资者和学术带头人，拥有漫长而卓越的职业生涯。Lange博士于1992年创立了CV Therapeutics，Inc.“CVT”和Nasdaq：CVTX，一家专注于心血管疾病的生物技术公司，并担任其董事长、首席执行官和首席科学官。Lange博士在获得5000万美元风险投资后，于1996年首次公开发行CVT，并监督了CVT的商业成功，引领了Ranexa和Lexiscan的增长，这两种药物的年销售额合计超过15亿美元。2009年，Lange博士将CVT以14亿美元的价格卖给了吉利德科学公司（Nasdaq：GILD），并在2019年之前一直担任兼职，担任高级顾问，在2018年之前向吉利德科学公司的首席执行官汇报工作。在成功销售CVT之后，Lange博士创立并出售了另外两家生物技术公司。2017年，GE Healthcare收购了其中一家公司Rapidscan Pharma Solutions Inc.（“RPS”），后者是一家用于心血管疾病诊断的生物制药应激剂开发商。2015年，Audentes Therapeutics, Inc.（Nasdaq：BOLD）收购了其中的第二家公司——基因治疗产品开发商Cardiogen Sciences，Inc；Lange博士继续担任首席董事，直到2020年以31亿美元将Audentes Therapeutics出售给Astellas Pharma Inc.（TYO：4503）。目前，Lange博士是Asset Management Ventures（以下简称“AMV”）的合伙人，该公司是一家早期风险投资公司，专注于数字健康、技术和生命科学领域的投资，处于生物技术领域关键创新趋势和交易流程的前沿。兰格博士在生物技术公司的各个领域领导了超过12项投资。除了Lange博士的运营和投资经验外，Lange博士在哈佛大学和华盛顿大学的学术医学领域工作了22年，他曾于1985-1992年在华盛顿大学医学院的犹太医院担任心脏病学主任和医学教授，并且是分子心脏病学领域的首批院士之一。目前，Lange博士担任罗切斯特大学董事会成员，自1998年以来一直担任这一职务。作为负责监督所有医疗业务的卫生事务委员会主席，Lange博士一直是医疗中心战略振兴领导团队的一员，负责监督项目，包括建造两座研究大楼和招聘100多名教职员工。Lange还领导了生物技术领域最受尊敬的行业和行业协会。从1999年到2009年，Lange博士担任生物技术创新组织的董事会成员，该组织是生物技术公司的贸易组织，领导了最大的成员公司委员会两年。Lange博士曾在非营利和营利性领域的许多其他公共和私人委员会任职，包括系统生物学研究所（“ISB”）和加州大学旧金山分校格拉德斯通研究所（UCSF Gladstone Institute），这是一个独立的、非营利性的生命科学研究机构，位于旧金山湾区生物医学和技术创新的中心。Lange拥有罗切斯特大学的学士学位、哈佛大学的医学博士学位和哈佛大学的生物化学博士学位。
Louis Lange, M.D., Ph.D., one of Epiphany Technology Acquisition Corp.'s Directors since September 2022 has a long and distinguished career as a leading entrepreneur, investor, and academic leader in the biotechnology sector. Dr. Lange founded CV Therapeutics, Inc. "CVT" and Nasdaq: CVTX, a biotechnology company focused on cardiovascular diseases, in 1992 and served as its chairman, chief executive officer and chief scientific officer. Dr. Lange led the initial public offering of CVT in 1996 after $50 million in venture investments and oversaw the commercial success of CVT, spearheading the growth of Ranexa and Lexiscan, two drugs with combined annual sales in excess of $1.5 billion dollars. Dr. Lange led the sale of CVT to Gilead Sciences, Inc. (Nasdaq: GILD) in 2009 for $1.4 billion, and stayed on part time until 2019 as a Senior Advisor reporting until 2018 to the Chief Executive Officer of Gilead Sciences. After successfully selling CVT, Dr. Lange founded and sold two additional biotechnology companies. In 2017 GE Healthcare acquired one of these companies, Rapidscan Pharma Solutions Inc. ("RPS"), a developer of a biopharmaceutical stress agent used in the diagnosis of cardiovascular disease. In 2015 Audentes Therapeutics, Inc. (Nasdaq: BOLD) acquired the second of these companies, gene therapy products developer Cardiogen Sciences, Inc.; Dr. Lange stayed on as lead director up to the sale of Audentes Therapeutics to Astellas Pharma Inc. (TYO:4503) in 2020 for $3.1 billion. Currently, Dr. Lange is a Partner at Asset Management Ventures ("AMV"), an early-stage venture capital firm focused on investments in the digital health, technology, and life sciences sectors, sitting at the forefront of key innovation trends and deal flow within the biotechnology space. Dr. Lange has led over 12 investments across all areas of biotechnology companies.In addition to Dr. Lange's operational and investing experience, Dr. Lange spent 22 years in academic medicine at Harvard University and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital at Washington University School of Medicine from 1985-1992 and was one of the first academicians in molecular cardiology. Currently, Dr. Lange serves as a member of the Board of Trustees at the University of Rochester, a role he has held since 1998. As Chair of the Health Affairs committee that oversees all of the medical operations, Dr. Lange has been part of the leadership team for strategic re-invigoration of the medical center, overseeing projects including construction of two research buildings and recruitment of over 100 faculty members.Dr. Lange has also led the most respected industry and trade associations in the biotechnology sector. From 1999 to 2009 Dr. Lange served on the Board of Directors of Biotechnology Innovation Organization, the trade organization of biotechnology companies, leading the largest committee of member companies for two years. Dr. Lange has been on numerous other public and private Boards in both the non-profit and for-profit arena, including the Institute of Systems Biology ("ISB"), a nonprofit biomedical research organization co-founded by industry stalwart Dr. Leroy ("Lee") Hood, and the UCSF Gladstone Institute, an independent, nonprofit life science research organization located in the epicenter of biomedical and technological innovation in the San Francisco Bay Area.Dr. Lange has a Bachelor's degree from the University of Rochester, an M.D. from Harvard University and a Ph.D. in Biological Chemistry, also from Harvard University. - Louis Lange，医学博士，自2022年9月起担任Epiphany Technology Acquisition Corp.的董事之一，作为生物技术领域领先的企业家、投资者和学术带头人，拥有漫长而卓越的职业生涯。Lange博士于1992年创立了CV Therapeutics，Inc.“CVT”和Nasdaq：CVTX，一家专注于心血管疾病的生物技术公司，并担任其董事长、首席执行官和首席科学官。Lange博士在获得5000万美元风险投资后，于1996年首次公开发行CVT，并监督了CVT的商业成功，引领了Ranexa和Lexiscan的增长，这两种药物的年销售额合计超过15亿美元。2009年，Lange博士将CVT以14亿美元的价格卖给了吉利德科学公司（Nasdaq：GILD），并在2019年之前一直担任兼职，担任高级顾问，在2018年之前向吉利德科学公司的首席执行官汇报工作。在成功销售CVT之后，Lange博士创立并出售了另外两家生物技术公司。2017年，GE Healthcare收购了其中一家公司Rapidscan Pharma Solutions Inc.（“RPS”），后者是一家用于心血管疾病诊断的生物制药应激剂开发商。2015年，Audentes Therapeutics, Inc.（Nasdaq：BOLD）收购了其中的第二家公司——基因治疗产品开发商Cardiogen Sciences，Inc；Lange博士继续担任首席董事，直到2020年以31亿美元将Audentes Therapeutics出售给Astellas Pharma Inc.（TYO：4503）。目前，Lange博士是Asset Management Ventures（以下简称“AMV”）的合伙人，该公司是一家早期风险投资公司，专注于数字健康、技术和生命科学领域的投资，处于生物技术领域关键创新趋势和交易流程的前沿。兰格博士在生物技术公司的各个领域领导了超过12项投资。除了Lange博士的运营和投资经验外，Lange博士在哈佛大学和华盛顿大学的学术医学领域工作了22年，他曾于1985-1992年在华盛顿大学医学院的犹太医院担任心脏病学主任和医学教授，并且是分子心脏病学领域的首批院士之一。目前，Lange博士担任罗切斯特大学董事会成员，自1998年以来一直担任这一职务。作为负责监督所有医疗业务的卫生事务委员会主席，Lange博士一直是医疗中心战略振兴领导团队的一员，负责监督项目，包括建造两座研究大楼和招聘100多名教职员工。Lange还领导了生物技术领域最受尊敬的行业和行业协会。从1999年到2009年，Lange博士担任生物技术创新组织的董事会成员，该组织是生物技术公司的贸易组织，领导了最大的成员公司委员会两年。Lange博士曾在非营利和营利性领域的许多其他公共和私人委员会任职，包括系统生物学研究所（“ISB”）和加州大学旧金山分校格拉德斯通研究所（UCSF Gladstone Institute），这是一个独立的、非营利性的生命科学研究机构，位于旧金山湾区生物医学和技术创新的中心。Lange拥有罗切斯特大学的学士学位、哈佛大学的医学博士学位和哈佛大学的生物化学博士学位。
- Louis Lange, M.D., Ph.D., one of Epiphany Technology Acquisition Corp.'s Directors since September 2022 has a long and distinguished career as a leading entrepreneur, investor, and academic leader in the biotechnology sector. Dr. Lange founded CV Therapeutics, Inc. "CVT" and Nasdaq: CVTX, a biotechnology company focused on cardiovascular diseases, in 1992 and served as its chairman, chief executive officer and chief scientific officer. Dr. Lange led the initial public offering of CVT in 1996 after $50 million in venture investments and oversaw the commercial success of CVT, spearheading the growth of Ranexa and Lexiscan, two drugs with combined annual sales in excess of $1.5 billion dollars. Dr. Lange led the sale of CVT to Gilead Sciences, Inc. (Nasdaq: GILD) in 2009 for $1.4 billion, and stayed on part time until 2019 as a Senior Advisor reporting until 2018 to the Chief Executive Officer of Gilead Sciences. After successfully selling CVT, Dr. Lange founded and sold two additional biotechnology companies. In 2017 GE Healthcare acquired one of these companies, Rapidscan Pharma Solutions Inc. ("RPS"), a developer of a biopharmaceutical stress agent used in the diagnosis of cardiovascular disease. In 2015 Audentes Therapeutics, Inc. (Nasdaq: BOLD) acquired the second of these companies, gene therapy products developer Cardiogen Sciences, Inc.; Dr. Lange stayed on as lead director up to the sale of Audentes Therapeutics to Astellas Pharma Inc. (TYO:4503) in 2020 for $3.1 billion. Currently, Dr. Lange is a Partner at Asset Management Ventures ("AMV"), an early-stage venture capital firm focused on investments in the digital health, technology, and life sciences sectors, sitting at the forefront of key innovation trends and deal flow within the biotechnology space. Dr. Lange has led over 12 investments across all areas of biotechnology companies.In addition to Dr. Lange's operational and investing experience, Dr. Lange spent 22 years in academic medicine at Harvard University and Washington University, where he served as Chief of Cardiology and Professor of Medicine at Jewish Hospital at Washington University School of Medicine from 1985-1992 and was one of the first academicians in molecular cardiology. Currently, Dr. Lange serves as a member of the Board of Trustees at the University of Rochester, a role he has held since 1998. As Chair of the Health Affairs committee that oversees all of the medical operations, Dr. Lange has been part of the leadership team for strategic re-invigoration of the medical center, overseeing projects including construction of two research buildings and recruitment of over 100 faculty members.Dr. Lange has also led the most respected industry and trade associations in the biotechnology sector. From 1999 to 2009 Dr. Lange served on the Board of Directors of Biotechnology Innovation Organization, the trade organization of biotechnology companies, leading the largest committee of member companies for two years. Dr. Lange has been on numerous other public and private Boards in both the non-profit and for-profit arena, including the Institute of Systems Biology ("ISB"), a nonprofit biomedical research organization co-founded by industry stalwart Dr. Leroy ("Lee") Hood, and the UCSF Gladstone Institute, an independent, nonprofit life science research organization located in the epicenter of biomedical and technological innovation in the San Francisco Bay Area.Dr. Lange has a Bachelor's degree from the University of Rochester, an M.D. from Harvard University and a Ph.D. in Biological Chemistry, also from Harvard University.
- Michael Davidson
-
Michael Davidson自2021年1月起担任董事会成员。戴维森博士是芝加哥大学的医学教授和脂质诊所主任。他还担任New Amsterdam Pharma的首席执行官。戴维森博士是脂类学领域的领先专家。他进行了1000多项临床试验，发表了350多篇医学期刊文章，并撰写了三本有关脂类学的书籍。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和欧米茄-3脂肪酸的广泛研究。Davidson博士创立了芝加哥临床研究中心，该中心成为美国最大的研究站点，并于1996年被Pharmaceutical产品开发收购。此外，他于2008年创立了Omthera Pharmaceuticals，该公司于2013年被阿斯利康（AstraZeneca）以4.4亿美元收购，最近，他担任Corvidia Therapeutics的创始首席执行官/CSO，该公司于2020年被Novo Nordisk以高达21亿美元的价格收购。Davidson博士获得了内科，心脏病学和临床脂类学的董事会认证。2010年至2011年，他担任美国国家血脂协会主席，被美国糖尿病协会评为过去15年来美国最好的医生之一，并于2010年被评为年度之父。他也是纳斯达克上市的Caladrius Bioscience的董事会成员。
Michael Davidson,was appointed as Newamsterdam Pharma Company N.V. Chief Executive Officer and executive director in November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from August 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co-founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX) and Silence Therapeutics plc (Nasdaq: SLN). Dr. Davidson also serves on the boards of two private biotechnology companies, Sonothera and NanoPhoria Bioscience. Dr. Davidson received his B.A. and M.S. from Northwestern University and his M.D. from The Ohio State University School of Medicine. - Michael Davidson自2021年1月起担任董事会成员。戴维森博士是芝加哥大学的医学教授和脂质诊所主任。他还担任New Amsterdam Pharma的首席执行官。戴维森博士是脂类学领域的领先专家。他进行了1000多项临床试验，发表了350多篇医学期刊文章，并撰写了三本有关脂类学的书籍。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和欧米茄-3脂肪酸的广泛研究。Davidson博士创立了芝加哥临床研究中心，该中心成为美国最大的研究站点，并于1996年被Pharmaceutical产品开发收购。此外，他于2008年创立了Omthera Pharmaceuticals，该公司于2013年被阿斯利康（AstraZeneca）以4.4亿美元收购，最近，他担任Corvidia Therapeutics的创始首席执行官/CSO，该公司于2020年被Novo Nordisk以高达21亿美元的价格收购。Davidson博士获得了内科，心脏病学和临床脂类学的董事会认证。2010年至2011年，他担任美国国家血脂协会主席，被美国糖尿病协会评为过去15年来美国最好的医生之一，并于2010年被评为年度之父。他也是纳斯达克上市的Caladrius Bioscience的董事会成员。
- Michael Davidson,was appointed as Newamsterdam Pharma Company N.V. Chief Executive Officer and executive director in November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from August 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co-founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX) and Silence Therapeutics plc (Nasdaq: SLN). Dr. Davidson also serves on the boards of two private biotechnology companies, Sonothera and NanoPhoria Bioscience. Dr. Davidson received his B.A. and M.S. from Northwestern University and his M.D. from The Ohio State University School of Medicine.
- Michael Davidson
-
Michael Davidson，于2022年11月被任命为Newamsterdam Pharma Company N.V.首席执行官兼执行董事。Davidson博士曾于2020年8月至2022年11月担任NewAmsterdam Pharma的首席执行官和执行董事。在加入NewAmsterdam Pharma之前，Davidson博士于2016年1月至2018年4月期间担任Corvidia Therapeutics，Inc.的创始人兼首席执行官，并于2018年4月至2020年7月期间担任首席科学/医疗官，当时Corvidia被Novo Nordisk A/S以高达21亿美元的价格收购。戴维森博士是脂质学领域的领先专家，过去15年被评为美国最佳医生，目前也是芝加哥大学的医学教授和脂质诊所主任。戴维森博士于2008年与他人共同创立并担任Omthera Pharmaceuticals，Inc.的首席医疗官，该公司后于2013年被阿斯利康制药公司以高达4.43亿美元的价格收购。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和omega-3脂肪酸的广泛研究。Davidson博士在内科、心脏病学和临床脂质学领域获得董事会认证，并于2010年至2011年担任美国国家脂质协会主席。Davidson博士目前在Tenax Therapeutics, Inc.（纳斯达克：TENX）和Silence Therapeutics plc（纳斯达克：SLN）的董事会任职。戴维森博士还在两家私营生物技术公司Sonothera和NanoPhoria Bioscience的董事会任职。Davidson博士获得了西北大学的学士和硕士学位，并获得了俄亥俄州立大学医学院的医学博士学位。
Michael Davidson,was appointed as Newamsterdam Pharma Company N.V. Chief Executive Officer and executive director in November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from August 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co-founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX) and Silence Therapeutics plc (Nasdaq: SLN). Dr. Davidson also serves on the boards of two private biotechnology companies, Sonothera and NanoPhoria Bioscience. Dr. Davidson received his B.A. and M.S. from Northwestern University and his M.D. from The Ohio State University School of Medicine. - Michael Davidson，于2022年11月被任命为Newamsterdam Pharma Company N.V.首席执行官兼执行董事。Davidson博士曾于2020年8月至2022年11月担任NewAmsterdam Pharma的首席执行官和执行董事。在加入NewAmsterdam Pharma之前，Davidson博士于2016年1月至2018年4月期间担任Corvidia Therapeutics，Inc.的创始人兼首席执行官，并于2018年4月至2020年7月期间担任首席科学/医疗官，当时Corvidia被Novo Nordisk A/S以高达21亿美元的价格收购。戴维森博士是脂质学领域的领先专家，过去15年被评为美国最佳医生，目前也是芝加哥大学的医学教授和脂质诊所主任。戴维森博士于2008年与他人共同创立并担任Omthera Pharmaceuticals，Inc.的首席医疗官，该公司后于2013年被阿斯利康制药公司以高达4.43亿美元的价格收购。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和omega-3脂肪酸的广泛研究。Davidson博士在内科、心脏病学和临床脂质学领域获得董事会认证，并于2010年至2011年担任美国国家脂质协会主席。Davidson博士目前在Tenax Therapeutics, Inc.（纳斯达克：TENX）和Silence Therapeutics plc（纳斯达克：SLN）的董事会任职。戴维森博士还在两家私营生物技术公司Sonothera和NanoPhoria Bioscience的董事会任职。Davidson博士获得了西北大学的学士和硕士学位，并获得了俄亥俄州立大学医学院的医学博士学位。
- Michael Davidson,was appointed as Newamsterdam Pharma Company N.V. Chief Executive Officer and executive director in November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from August 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co-founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX) and Silence Therapeutics plc (Nasdaq: SLN). Dr. Davidson also serves on the boards of two private biotechnology companies, Sonothera and NanoPhoria Bioscience. Dr. Davidson received his B.A. and M.S. from Northwestern University and his M.D. from The Ohio State University School of Medicine.
- John Kastelein
-
John Kastelein，于2022年11月被任命为Newamsterdam Pharma Company N.V.首席科学官和非执行董事。Kastelein博士于2020年共同创立了NewAmsterdam Pharma，于2020年1月1日至2022年11月期间担任其首席科学官和执行董事。Kastelein博士还自2013年1月起担任Vascular Research Network Inc.（“VRN”）的首席执行官，并自2018年1月起担任Staten Biotechnology B.V.的首席医疗官。Kastelein博士还担任名誉医学教授，并曾担任阿姆斯特丹大学学术医学中心血管医学系主任。他在荷兰动脉粥样硬化学会顾问委员会任职。2011年，他因在基因治疗领域的研究获得了ZonMW珍珠。Kastelein博士还担任North Sea Therapeutics Inc.、VRN和Oxitope Pharma Inc.的董事会成员。Kastelein博士还担任多家生物技术和制药公司的顾问。Kastelein博士获得阿姆斯特丹大学医学博士学位（荣誉），在阿姆斯特丹大学学术医学中心接受内科培训，在温哥华的不列颠哥伦比亚大学接受脂质学和分子生物学培训。Kastelein博士于1997年在《新英格兰医学杂志》上发表了他关于CETP抑制的首个临床研究。
John Kastelein,was appointed as Newamsterdam Pharma Company N.V. Chief Scientific Officer and non-executive director in November 2022. Dr. Kastelein co-founded NewAmsterdam Pharma in 2020 served as its Chief Scientific Officer and an executive director from January 1, 2020 to November 2022. Dr. Kastelein has also served as the chief executive officer of Vascular Research Network Inc. ("VRN") since January 2013 and as the Chief Medical Officer of Staten Biotechnology B.V. since January 2018. Dr. Kastelein also serves as emeritus professor of medicine and was the chair of the department of vascular medicine at the Academic Medical Center of the University of Amsterdam. He serves on the advisory board of the Dutch Atherosclerosis Society. In 2011 he received the ZonMw Pearl for his research in the field of gene therapy. Dr. Kastelein also serves on the board of directors of North Sea Therapeutics Inc., VRN and Oxitope Pharma Inc. Dr. Kastelein also serves as an advisor to a number of biotech and pharmaceutical companies. Dr. Kastelein was awarded a doctorate in medicine (with honors) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. Dr. Kastelein published his first clinical research on CETP-inhibition in the New England Journal of Medicine in 1997. - John Kastelein，于2022年11月被任命为Newamsterdam Pharma Company N.V.首席科学官和非执行董事。Kastelein博士于2020年共同创立了NewAmsterdam Pharma，于2020年1月1日至2022年11月期间担任其首席科学官和执行董事。Kastelein博士还自2013年1月起担任Vascular Research Network Inc.（“VRN”）的首席执行官，并自2018年1月起担任Staten Biotechnology B.V.的首席医疗官。Kastelein博士还担任名誉医学教授，并曾担任阿姆斯特丹大学学术医学中心血管医学系主任。他在荷兰动脉粥样硬化学会顾问委员会任职。2011年，他因在基因治疗领域的研究获得了ZonMW珍珠。Kastelein博士还担任North Sea Therapeutics Inc.、VRN和Oxitope Pharma Inc.的董事会成员。Kastelein博士还担任多家生物技术和制药公司的顾问。Kastelein博士获得阿姆斯特丹大学医学博士学位（荣誉），在阿姆斯特丹大学学术医学中心接受内科培训，在温哥华的不列颠哥伦比亚大学接受脂质学和分子生物学培训。Kastelein博士于1997年在《新英格兰医学杂志》上发表了他关于CETP抑制的首个临床研究。
- John Kastelein,was appointed as Newamsterdam Pharma Company N.V. Chief Scientific Officer and non-executive director in November 2022. Dr. Kastelein co-founded NewAmsterdam Pharma in 2020 served as its Chief Scientific Officer and an executive director from January 1, 2020 to November 2022. Dr. Kastelein has also served as the chief executive officer of Vascular Research Network Inc. ("VRN") since January 2013 and as the Chief Medical Officer of Staten Biotechnology B.V. since January 2018. Dr. Kastelein also serves as emeritus professor of medicine and was the chair of the department of vascular medicine at the Academic Medical Center of the University of Amsterdam. He serves on the advisory board of the Dutch Atherosclerosis Society. In 2011 he received the ZonMw Pearl for his research in the field of gene therapy. Dr. Kastelein also serves on the board of directors of North Sea Therapeutics Inc., VRN and Oxitope Pharma Inc. Dr. Kastelein also serves as an advisor to a number of biotech and pharmaceutical companies. Dr. Kastelein was awarded a doctorate in medicine (with honors) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. Dr. Kastelein published his first clinical research on CETP-inhibition in the New England Journal of Medicine in 1997.
- Juliette Audet
-
Juliette Audet，于2022年11月被任命为董事会成员。奥德特女士此前曾于2020年至2022年11月在纽阿姆斯特丹制药公司董事会任职。Audet女士自2021年1月起担任Forbion Venture Capital的合伙人，并于2019年10月至2020年12月期间担任Forbion的负责人。在加入Forbion之前，Audet女士在2018年1月至2019年7月期间担任位于马萨诸塞州剑桥市的诺华风险基金的负责人。Audet女士目前担任Mestag Therapeutics Limited的董事会成员。Audet女士以优异的成绩获得了哈佛商学院的工商管理硕士学位和EPFL（瑞士联邦理工学院洛桑）的物理学硕士学位。
Juliette Audet,was appointed to the Board of Directors in November 2022. Ms. Audet previously served on the NewAmsterdam Pharma board from 2020 until November 2022. Ms. Audet has been a partner at Forbion Venture Capital since January 2021 and served as a principal at Forbion from October 2019 until December 2020. Prior to joining Forbion, Ms. Audet was a Principal at Novartis Venture Fund based in Cambridge, Massachusetts from January 2018 until July 2019. Ms. Audet currently serves on the board of directors of Mestag Therapeutics Limited. Ms. Audet received an M.B.A., with distinction, from Harvard Business School and her M.Sc in physics from EPFL (Lausanne, Swiss Federal Institute of Technology). - Juliette Audet，于2022年11月被任命为董事会成员。奥德特女士此前曾于2020年至2022年11月在纽阿姆斯特丹制药公司董事会任职。Audet女士自2021年1月起担任Forbion Venture Capital的合伙人，并于2019年10月至2020年12月期间担任Forbion的负责人。在加入Forbion之前，Audet女士在2018年1月至2019年7月期间担任位于马萨诸塞州剑桥市的诺华风险基金的负责人。Audet女士目前担任Mestag Therapeutics Limited的董事会成员。Audet女士以优异的成绩获得了哈佛商学院的工商管理硕士学位和EPFL（瑞士联邦理工学院洛桑）的物理学硕士学位。
- Juliette Audet,was appointed to the Board of Directors in November 2022. Ms. Audet previously served on the NewAmsterdam Pharma board from 2020 until November 2022. Ms. Audet has been a partner at Forbion Venture Capital since January 2021 and served as a principal at Forbion from October 2019 until December 2020. Prior to joining Forbion, Ms. Audet was a Principal at Novartis Venture Fund based in Cambridge, Massachusetts from January 2018 until July 2019. Ms. Audet currently serves on the board of directors of Mestag Therapeutics Limited. Ms. Audet received an M.B.A., with distinction, from Harvard Business School and her M.Sc in physics from EPFL (Lausanne, Swiss Federal Institute of Technology).
- Sander Slootweg
-
Sander Slootweg，于2022年11月被任命为董事会成员。Slootweg先生此前曾于2020年至2022年11月在纽阿姆斯特丹制药公司董事会任职。Slootweg先生与他人共同创立了Forbion，自2006年以来一直担任管理合伙人。Slootweg先生目前在Forbion多家投资组合公司的董事会任职，包括Replimune Group Inc.、NorthSea Therapeutics B.V.、Azafaros B.V.、Xention、Oxyrane Belgium NV和Forbion European收购公司（纳斯达克：FRBN）。Slootweg先生负责了几项重大退出：Forbion在Argenx SE（纳斯达克：ARGX）中的主要地位、Dezima在2015年被安进以高达15.5亿美元的价格收购以及在2011年以高达10亿美元的价格将Biovex Group，Inc.出售给TERM3。Slootweg先生此前曾在Pulmagen Therapeutics、Fovea Pharmaceuticals SA（2009年出售给Sanofi-aventis）、uniQure N.V.（2014年在纳斯达克首次公开发行股票）、Argenta Limited（2010年出售给Galapagos NV）、Alantos Pharmaceuticals，Inc.（2007年出售给安进）、Impella CardioSystems AG（2005年出售给Abiomed Inc.）、Pieris制药公司（2015年在纳斯达克纳斯达克首次公开发行股票）的董事会任职。在共同创立Forbion之前，Slootweg先生是ABN AMRO Capital Life Sciences的投资总监。Slootweg先生拥有阿姆斯特丹自由大学的商业和金融经济学学位以及荷兰Nijenrode大学的工商管理学位。
Sander Slootweg,was appointed to the Board of Directors in November 2022. Mr. Slootweg previously served on the NewAmsterdam Pharma board from 2020 until November 2022. Mr. Slootweg co-founded Forbion and has served as managing partner since 2006. Mr. Slootweg currently serves on the boards of several of Forbion's portfolio companies including Replimune Group Inc., NorthSea Therapeutics B.V., Azafaros B.V., Xention, Oxyrane Belgium NV and Forbion European Acquisition Corporation (Nasdaq: FRBN). Mr. Slootweg was responsible for several substantial exits: Forbion's major position in Argenx SE (Nasdaq: ARGX), Dezima's acquisition by Amgen in 2015 for up to $1.55 billion and the sale of Biovex Group, Inc. to Amgen in 2011 for up to $1 billion. Mr. Slootweg has previously served on the boards of Pulmagen Therapeutics, Fovea Pharmaceuticals SA (sold to Sanofi-aventis in 2009), uniQure N.V. (IPO on Nasdaq in 2014), Argenta Limited (sold to Galapagos NV in 2010), Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007), Impella CardioSystems AG (sold to Abiomed Inc. in 2005), Pieris Pharmaceuticals, Inc. (IPO on Nasdaq in 2015). Before co-founding Forbion, Mr. Slootweg was an investment director at ABN AMRO Capital Life Sciences. Mr. Slootweg holds degrees in business and financial economics from the Free University of Amsterdam and business administration from Nijenrode University, The Netherlands. - Sander Slootweg，于2022年11月被任命为董事会成员。Slootweg先生此前曾于2020年至2022年11月在纽阿姆斯特丹制药公司董事会任职。Slootweg先生与他人共同创立了Forbion，自2006年以来一直担任管理合伙人。Slootweg先生目前在Forbion多家投资组合公司的董事会任职，包括Replimune Group Inc.、NorthSea Therapeutics B.V.、Azafaros B.V.、Xention、Oxyrane Belgium NV和Forbion European收购公司（纳斯达克：FRBN）。Slootweg先生负责了几项重大退出：Forbion在Argenx SE（纳斯达克：ARGX）中的主要地位、Dezima在2015年被安进以高达15.5亿美元的价格收购以及在2011年以高达10亿美元的价格将Biovex Group，Inc.出售给TERM3。Slootweg先生此前曾在Pulmagen Therapeutics、Fovea Pharmaceuticals SA（2009年出售给Sanofi-aventis）、uniQure N.V.（2014年在纳斯达克首次公开发行股票）、Argenta Limited（2010年出售给Galapagos NV）、Alantos Pharmaceuticals，Inc.（2007年出售给安进）、Impella CardioSystems AG（2005年出售给Abiomed Inc.）、Pieris制药公司（2015年在纳斯达克纳斯达克首次公开发行股票）的董事会任职。在共同创立Forbion之前，Slootweg先生是ABN AMRO Capital Life Sciences的投资总监。Slootweg先生拥有阿姆斯特丹自由大学的商业和金融经济学学位以及荷兰Nijenrode大学的工商管理学位。
- Sander Slootweg,was appointed to the Board of Directors in November 2022. Mr. Slootweg previously served on the NewAmsterdam Pharma board from 2020 until November 2022. Mr. Slootweg co-founded Forbion and has served as managing partner since 2006. Mr. Slootweg currently serves on the boards of several of Forbion's portfolio companies including Replimune Group Inc., NorthSea Therapeutics B.V., Azafaros B.V., Xention, Oxyrane Belgium NV and Forbion European Acquisition Corporation (Nasdaq: FRBN). Mr. Slootweg was responsible for several substantial exits: Forbion's major position in Argenx SE (Nasdaq: ARGX), Dezima's acquisition by Amgen in 2015 for up to $1.55 billion and the sale of Biovex Group, Inc. to Amgen in 2011 for up to $1 billion. Mr. Slootweg has previously served on the boards of Pulmagen Therapeutics, Fovea Pharmaceuticals SA (sold to Sanofi-aventis in 2009), uniQure N.V. (IPO on Nasdaq in 2014), Argenta Limited (sold to Galapagos NV in 2010), Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007), Impella CardioSystems AG (sold to Abiomed Inc. in 2005), Pieris Pharmaceuticals, Inc. (IPO on Nasdaq in 2015). Before co-founding Forbion, Mr. Slootweg was an investment director at ABN AMRO Capital Life Sciences. Mr. Slootweg holds degrees in business and financial economics from the Free University of Amsterdam and business administration from Nijenrode University, The Netherlands.
- Nicholas Downing
-
尼古拉斯·唐宁，于2022年11月被任命为董事会成员。唐宁博士于2018年加入贝恩资本生命科学公司，目前担任合伙人。在加入贝恩资本之前，唐宁博士在2015年至2018年期间担任波士顿布莱根妇女医院的住院医师，在那里他在住院医疗服务和门诊中照顾患者。在他的整个医学生涯中，唐宁博士一直是积极的健康政策研究人员，并在同行评审的科学文献中撰写了40多篇文章。在从事医疗职业之前，唐宁博士是麦肯锡公司的一名顾问，在那里他与制药、医院和金融服务行业的客户就广泛的战略问题进行了合作。唐宁博士还担任Kestra Medical Technologies，Ltd.、Cardurion Pharmaceuticals，Inc.和River Renal Companies的董事会董事。唐宁博士以优异成绩毕业于哈佛学院，获得化学学位。他以优异成绩获得耶鲁大学医学院医学博士学位。
Nicholas Downing,was appointed to the Board of Directors in November 2022. Dr. Downing joined Bain Capital Life Sciences in 2018 where he currently serves as a Partner. Prior to joining Bain Capital, Dr. Downing was a resident physician at the Brigham and Women's Hospital in Boston from 2015 until 2018, where he cared for patients on the inpatient medical service and in the outpatient clinic. Throughout his medical career, Dr. Downing has been an active health policy researcher and is the author of over 40 articles in the peer-reviewed scientific literature. Prior to his medical career, Dr. Downing was a consultant at McKinsey and Company where he worked with clients in the pharmaceutical, hospital and financial services industries on a wide range of strategic problems. Dr. Downing also serves as a director on the board of Kestra Medical Technologies, Ltd., Cardurion Pharmaceuticals, Inc. and River Renal Companies. Dr. Downing graduated from Harvard College magna cum laude with a degree in chemistry. He received an M.D. cum laude from Yale University School of Medicine. - 尼古拉斯·唐宁，于2022年11月被任命为董事会成员。唐宁博士于2018年加入贝恩资本生命科学公司，目前担任合伙人。在加入贝恩资本之前，唐宁博士在2015年至2018年期间担任波士顿布莱根妇女医院的住院医师，在那里他在住院医疗服务和门诊中照顾患者。在他的整个医学生涯中，唐宁博士一直是积极的健康政策研究人员，并在同行评审的科学文献中撰写了40多篇文章。在从事医疗职业之前，唐宁博士是麦肯锡公司的一名顾问，在那里他与制药、医院和金融服务行业的客户就广泛的战略问题进行了合作。唐宁博士还担任Kestra Medical Technologies，Ltd.、Cardurion Pharmaceuticals，Inc.和River Renal Companies的董事会董事。唐宁博士以优异成绩毕业于哈佛学院，获得化学学位。他以优异成绩获得耶鲁大学医学院医学博士学位。
- Nicholas Downing,was appointed to the Board of Directors in November 2022. Dr. Downing joined Bain Capital Life Sciences in 2018 where he currently serves as a Partner. Prior to joining Bain Capital, Dr. Downing was a resident physician at the Brigham and Women's Hospital in Boston from 2015 until 2018, where he cared for patients on the inpatient medical service and in the outpatient clinic. Throughout his medical career, Dr. Downing has been an active health policy researcher and is the author of over 40 articles in the peer-reviewed scientific literature. Prior to his medical career, Dr. Downing was a consultant at McKinsey and Company where he worked with clients in the pharmaceutical, hospital and financial services industries on a wide range of strategic problems. Dr. Downing also serves as a director on the board of Kestra Medical Technologies, Ltd., Cardurion Pharmaceuticals, Inc. and River Renal Companies. Dr. Downing graduated from Harvard College magna cum laude with a degree in chemistry. He received an M.D. cum laude from Yale University School of Medicine.
- John W. Smither
-
John W. Smither，此前曾于2019年5月至2021年3月期间担任Arcutis Biotherapeutics, Inc.，Inc.（纳斯达克：ARQT）的首席财务官；于2018年4月至2019年3月期间担任Sienna Biopharmaceuticals, Inc.，Inc.（纳斯达克：SNNA）的首席财务官的TERM5。Smither先生还于2017年10月至2018年4月在与Gilead的整合期间担任Kite Pharma（吉利德科学，Inc.旗下公司）的临时首席财务官。Smither先生目前在eFFECTOR Therapeutics，Inc.（纳斯达克：EFTR）和Applied Molecular Transport，Inc.（纳斯达克：AMTI）的董事会和审计委员会主席中任职。Smither先生还分别担任eFFECTOR治疗公司和Applied Molecular运输公司的提名和公司治理委员会以及薪酬委员会的成员。Smither先生此前曾在Achaogen，Inc.和Principia Biopharma Inc.Biopharma Inc.的董事会任职。TERM1 Smither先生还拥有15年的执业注册会计师（非在职）经验，其中包括在Ernst & Young LLP担任审计合伙人的时间。
John W. Smither,previously served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) from May 2019 until March 2021 and the Chief Financial Officer of Sienna Biopharmaceuticals, Inc. (Nasdaq: SNNA) from April 2018 until March 2019. Mr. Smither also served as the interim Chief Financial Officer at Kite Pharma (a Gilead Sciences, Inc. company) from October 2017 until April 2018 during its integration with Gilead. Mr. Smither currently serves on the board of directors and audit committee chair of eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) and Applied Molecular Transport, Inc. (Nasdaq: AMTI). Mr. Smither also serves as a member of the nomination and corporate governance committee and the compensation committee of eFFECTOR Therapeutics and Applied Molecular Transport, respectively. Mr. Smither previously served on the board of directors of Achaogen, Inc. and Principia Biopharma Inc. Mr. Smither also has 15 years' experience as a practicing CPA (inactive), including time spent as an audit partner with Ernst & Young LLP. - John W. Smither，此前曾于2019年5月至2021年3月期间担任Arcutis Biotherapeutics, Inc.，Inc.（纳斯达克：ARQT）的首席财务官；于2018年4月至2019年3月期间担任Sienna Biopharmaceuticals, Inc.，Inc.（纳斯达克：SNNA）的首席财务官的TERM5。Smither先生还于2017年10月至2018年4月在与Gilead的整合期间担任Kite Pharma（吉利德科学，Inc.旗下公司）的临时首席财务官。Smither先生目前在eFFECTOR Therapeutics，Inc.（纳斯达克：EFTR）和Applied Molecular Transport，Inc.（纳斯达克：AMTI）的董事会和审计委员会主席中任职。Smither先生还分别担任eFFECTOR治疗公司和Applied Molecular运输公司的提名和公司治理委员会以及薪酬委员会的成员。Smither先生此前曾在Achaogen，Inc.和Principia Biopharma Inc.Biopharma Inc.的董事会任职。TERM1 Smither先生还拥有15年的执业注册会计师（非在职）经验，其中包括在Ernst & Young LLP担任审计合伙人的时间。
- John W. Smither,previously served as the Chief Financial Officer of Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) from May 2019 until March 2021 and the Chief Financial Officer of Sienna Biopharmaceuticals, Inc. (Nasdaq: SNNA) from April 2018 until March 2019. Mr. Smither also served as the interim Chief Financial Officer at Kite Pharma (a Gilead Sciences, Inc. company) from October 2017 until April 2018 during its integration with Gilead. Mr. Smither currently serves on the board of directors and audit committee chair of eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) and Applied Molecular Transport, Inc. (Nasdaq: AMTI). Mr. Smither also serves as a member of the nomination and corporate governance committee and the compensation committee of eFFECTOR Therapeutics and Applied Molecular Transport, respectively. Mr. Smither previously served on the board of directors of Achaogen, Inc. and Principia Biopharma Inc. Mr. Smither also has 15 years' experience as a practicing CPA (inactive), including time spent as an audit partner with Ernst & Young LLP.
- Janneke van der Kamp
-
Janneke van der Kamp目前担任Gr ü nenthal的首席商务官，此前在诺华担任了20年的职责，最终在制药执行委员会担任产品和投资组合战略全球主管，然后在2017年1月至2022年1月期间担任欧洲制药区域主管。在诺华期间，van der Kamp女士支持推出诺华的关键心血管疾病药物，以及该公司在免疫学、皮肤病学、神经科学、眼科和呼吸系统疾病方面的努力。van der Kamp女士获得了乌得勒支大学的化学硕士学位和欧洲工商管理学院的工商管理硕士学位。
Janneke van der Kamp,currently serves as the Chief Commercial Officer of Grünenthal and previously spent two decades in roles of increasing responsibility at Novartis, ultimately serving on the Pharma Executive Committee as Global Head of Product & Portfolio Strategy and then Head of Pharma Region Europe from January 2017 until January 2022. While at Novartis, Ms. van der Kamp supported the launch of Novartis' key cardiovascular disease medicines, as well as the company's efforts in immunology, dermatology, neuroscience, ophthalmology, and respiratory disease. Ms. van der Kamp received her M.S. in chemistry from Utrecht University and M.B.A. from INSEAD. - Janneke van der Kamp目前担任Gr ü nenthal的首席商务官，此前在诺华担任了20年的职责，最终在制药执行委员会担任产品和投资组合战略全球主管，然后在2017年1月至2022年1月期间担任欧洲制药区域主管。在诺华期间，van der Kamp女士支持推出诺华的关键心血管疾病药物，以及该公司在免疫学、皮肤病学、神经科学、眼科和呼吸系统疾病方面的努力。van der Kamp女士获得了乌得勒支大学的化学硕士学位和欧洲工商管理学院的工商管理硕士学位。
- Janneke van der Kamp,currently serves as the Chief Commercial Officer of Grünenthal and previously spent two decades in roles of increasing responsibility at Novartis, ultimately serving on the Pharma Executive Committee as Global Head of Product & Portfolio Strategy and then Head of Pharma Region Europe from January 2017 until January 2022. While at Novartis, Ms. van der Kamp supported the launch of Novartis' key cardiovascular disease medicines, as well as the company's efforts in immunology, dermatology, neuroscience, ophthalmology, and respiratory disease. Ms. van der Kamp received her M.S. in chemistry from Utrecht University and M.B.A. from INSEAD.
- James N. Topper
-
James N. Topper，医学博士，担任首席执行官兼董事会主席。Topper博士目前是Frazier Life Sciences的管理合伙人。他于2003年加入弗雷泽，并于同年开设了弗雷泽的门洛帕克办事处。在15年的管理合伙人生涯中，Topper博士投资了超过35家公司，涵盖了广泛的生命科学和生物制药公司。Topper博士领导并担任过弗雷泽许多成功的生命科学投资的董事会成员，包括出售给阿斯利康的Acerta Pharma BV、Calistoga Pharmaceuticals（联合创始人，出售给Gilead Sciences）、Mavupharma（出售给艾伯维）、Rempex（出售给The Medicines Company）、Incline（联合创始人，出售给The Medicines Company）、Alnara（出售给礼来）、Portola（联合创始人，纳斯达克股票代码：PTLA）、CoTherix（出售给Actelion）和Threshold（纳斯达克股票代码：THLD）。他目前在Allena制药（纳斯达克股票代码：ALNA）、Alpine Immune科学（纳斯达克股票代码：ALPN）、Amunix制药、AnaptysBio（纳斯达克股票代码：ANAB）、Lassen Therapeutics、Seraxis Holdings，Inc.和Phathom制药（纳斯达克股票代码：PHAT）中代表弗雷泽参选。2011年和2016年，托珀博士入选Midas最佳风险投资家榜单，2013年，托珀博士被《福布斯》评为十大医疗保健投资者。
James N. Topper,was appointed to the Board of Directors in November 2022. Dr. Topper previously served as FLAC's Chief Executive Officer and Chairman of the FLAC Board from October 2020 until November 2022. Dr. Topper currently serves as a Managing Partner of Frazier Life Sciences ("Frazier"). He joined Frazier in 2003 and opened Frazier's Menlo Park office in the same year. Throughout his 15 years as a Managing Partner, Dr. Topper has invested across over 35 companies encompassing a broad spectrum of life science and biopharmaceutical companies. Dr. Topper has led and served as a board member for many of Frazier's successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Amunix Pharmaceuticals, Inc. (sold to Sanofi), Aptinyx Inc. (Nasdaq: APTX), Calistoga Pharmaceuticals, Inc. (co-founder, sold to Gilead Sciences), Entasis Therapeutics Holdings Inc. (sold to Innoviva), Frazier Lifesciences Acquisition Corporation, Mavupharma (sold to AbbVie), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola, Inc. (co-founder, Nasdaq: PTLA), Phathom Pharmaceuticals Inc. (Nasdaq: PHAT), CoTherix, Inc (sold to Actelion), and Threshold Pharmaceutical, Inc. (Nasdaq: THLD). He currently represents Frazier on the boards of Alpine Immune Sciences (Nasdaq: ALPN), AnaptysBio, Inc. (Nasdaq: ANAB), Lassen Therapeutics, Seraxis Holdings, Inc., Enlaza Therapeutics, Inc., Serum, Inc. and Sudo Biosciences, Inc. In 2011 and 2016, Dr. Topper was named to the Midas List of leading venture capitalists, and in 2013, Dr. Topper was recognized by Forbes as a top ten healthcare investor. Dr. Topper received his M.D. and Ph.D. in Biophysics from Stanford and his B.S. from the University of Michigan. - James N. Topper，医学博士，担任首席执行官兼董事会主席。Topper博士目前是Frazier Life Sciences的管理合伙人。他于2003年加入弗雷泽，并于同年开设了弗雷泽的门洛帕克办事处。在15年的管理合伙人生涯中，Topper博士投资了超过35家公司，涵盖了广泛的生命科学和生物制药公司。Topper博士领导并担任过弗雷泽许多成功的生命科学投资的董事会成员，包括出售给阿斯利康的Acerta Pharma BV、Calistoga Pharmaceuticals（联合创始人，出售给Gilead Sciences）、Mavupharma（出售给艾伯维）、Rempex（出售给The Medicines Company）、Incline（联合创始人，出售给The Medicines Company）、Alnara（出售给礼来）、Portola（联合创始人，纳斯达克股票代码：PTLA）、CoTherix（出售给Actelion）和Threshold（纳斯达克股票代码：THLD）。他目前在Allena制药（纳斯达克股票代码：ALNA）、Alpine Immune科学（纳斯达克股票代码：ALPN）、Amunix制药、AnaptysBio（纳斯达克股票代码：ANAB）、Lassen Therapeutics、Seraxis Holdings，Inc.和Phathom制药（纳斯达克股票代码：PHAT）中代表弗雷泽参选。2011年和2016年，托珀博士入选Midas最佳风险投资家榜单，2013年，托珀博士被《福布斯》评为十大医疗保健投资者。
- James N. Topper,was appointed to the Board of Directors in November 2022. Dr. Topper previously served as FLAC's Chief Executive Officer and Chairman of the FLAC Board from October 2020 until November 2022. Dr. Topper currently serves as a Managing Partner of Frazier Life Sciences ("Frazier"). He joined Frazier in 2003 and opened Frazier's Menlo Park office in the same year. Throughout his 15 years as a Managing Partner, Dr. Topper has invested across over 35 companies encompassing a broad spectrum of life science and biopharmaceutical companies. Dr. Topper has led and served as a board member for many of Frazier's successful life sciences investments, including Acerta Pharma BV (sold to AstraZeneca), Amunix Pharmaceuticals, Inc. (sold to Sanofi), Aptinyx Inc. (Nasdaq: APTX), Calistoga Pharmaceuticals, Inc. (co-founder, sold to Gilead Sciences), Entasis Therapeutics Holdings Inc. (sold to Innoviva), Frazier Lifesciences Acquisition Corporation, Mavupharma (sold to AbbVie), Rempex (sold to The Medicines Company), Incline (co-founder, sold to The Medicines Company), Alnara (sold to Lilly), Portola, Inc. (co-founder, Nasdaq: PTLA), Phathom Pharmaceuticals Inc. (Nasdaq: PHAT), CoTherix, Inc (sold to Actelion), and Threshold Pharmaceutical, Inc. (Nasdaq: THLD). He currently represents Frazier on the boards of Alpine Immune Sciences (Nasdaq: ALPN), AnaptysBio, Inc. (Nasdaq: ANAB), Lassen Therapeutics, Seraxis Holdings, Inc., Enlaza Therapeutics, Inc., Serum, Inc. and Sudo Biosciences, Inc. In 2011 and 2016, Dr. Topper was named to the Midas List of leading venture capitalists, and in 2013, Dr. Topper was recognized by Forbes as a top ten healthcare investor. Dr. Topper received his M.D. and Ph.D. in Biophysics from Stanford and his B.S. from the University of Michigan.
- Sander Slootweg
-
Sander Slootweg，于2022年11月被任命为董事会成员。Slootweg先生此前曾在NewAmsterdam Pharma董事会任职，任职时间为2020年至2022年11月。Slootweg先生与他人共同创立了Forbion，自2006年以来一直担任管理合伙人。Slootweg先生目前在Forbion多家投资组合公司的董事会任职，包括Replimune Group Inc.、NorthSea Therapeutics B.V.、Azafaros B.V.、Xention、Oxyrane Belgium NV和Forbion European Acquisition Corporation（FRBN）。Slootweg先生负责了几项重大退出：Forbion在Argenx SE（纳斯达克：ARGX）中的主要地位，Dezima在2015年被安进以高达15.5亿美元的价格收购，以及在2011年以高达10亿美元的价格将Biovex Group，Inc.出售给TERM3。Slootweg先生此前曾在Pulmagen Therapeutics、Fovea Pharmaceuticals SA（2009年出售给Sanofi-aventis）、uniQure N.V.（2014年在纳斯达克首次公开发行股票）、Argenta Limited（2010年出售给Galapagos NV）、Alantos Pharmaceuticals，Inc.（2007年出售给安进）、Impella CardioSystems AG（2005年出售给Abiomed Inc.）、Pieris制药公司（2015年在纳斯达克首次公开发行股票）的董事会任职。在共同创立Forbion之前，Slootweg先生是ABN AMRO Capital Life Sciences的投资总监。Slootweg先生拥有阿姆斯特丹大学的商业和金融经济学学位以及荷兰Nijenrode大学的工商管理学位。
Sander Slootweg, was appointed to the Board of Directors in November 2022. Mr. Slootweg previously served on the NewAmsterdam Pharma board from 2020 until November 2022. Mr. Slootweg co-founded Forbion and has served as managing partner since 2006. Mr. Slootweg currently serves on the boards of several of Forbion's portfolio companies including Replimune Group Inc., NorthSea Therapeutics B.V., Azafaros B.V., Xention, Oxyrane Belgium NV and Forbion European Acquisition Corporation (Nasdaq: FRBN). Mr. Slootweg was responsible for several substantial exits: Forbion's major position in Argenx SE (Nasdaq: ARGX), Dezima's acquisition by Amgen in 2015 for up to $1.55 billion and the sale of Biovex Group, Inc. to Amgen in 2011 for up to $1 billion. Mr. Slootweg has previously served on the boards of Pulmagen Therapeutics, Fovea Pharmaceuticals SA (sold to Sanofi-aventis in 2009), uniQure N.V. (IPO on Nasdaq in 2014), Argenta Limited (sold to Galapagos NV in 2010), Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007), Impella CardioSystems AG (sold to Abiomed Inc. in 2005), Pieris Pharmaceuticals, Inc. (IPO on Nasdaq in 2015). Before co-founding Forbion, Mr. Slootweg was an investment director at ABN AMRO Capital Life Sciences. Mr. Slootweg holds degrees in business and financial economics from the Free University of Amsterdam and business administration from Nijenrode University, The Netherlands. - Sander Slootweg，于2022年11月被任命为董事会成员。Slootweg先生此前曾在NewAmsterdam Pharma董事会任职，任职时间为2020年至2022年11月。Slootweg先生与他人共同创立了Forbion，自2006年以来一直担任管理合伙人。Slootweg先生目前在Forbion多家投资组合公司的董事会任职，包括Replimune Group Inc.、NorthSea Therapeutics B.V.、Azafaros B.V.、Xention、Oxyrane Belgium NV和Forbion European Acquisition Corporation（FRBN）。Slootweg先生负责了几项重大退出：Forbion在Argenx SE（纳斯达克：ARGX）中的主要地位，Dezima在2015年被安进以高达15.5亿美元的价格收购，以及在2011年以高达10亿美元的价格将Biovex Group，Inc.出售给TERM3。Slootweg先生此前曾在Pulmagen Therapeutics、Fovea Pharmaceuticals SA（2009年出售给Sanofi-aventis）、uniQure N.V.（2014年在纳斯达克首次公开发行股票）、Argenta Limited（2010年出售给Galapagos NV）、Alantos Pharmaceuticals，Inc.（2007年出售给安进）、Impella CardioSystems AG（2005年出售给Abiomed Inc.）、Pieris制药公司（2015年在纳斯达克首次公开发行股票）的董事会任职。在共同创立Forbion之前，Slootweg先生是ABN AMRO Capital Life Sciences的投资总监。Slootweg先生拥有阿姆斯特丹大学的商业和金融经济学学位以及荷兰Nijenrode大学的工商管理学位。
- Sander Slootweg, was appointed to the Board of Directors in November 2022. Mr. Slootweg previously served on the NewAmsterdam Pharma board from 2020 until November 2022. Mr. Slootweg co-founded Forbion and has served as managing partner since 2006. Mr. Slootweg currently serves on the boards of several of Forbion's portfolio companies including Replimune Group Inc., NorthSea Therapeutics B.V., Azafaros B.V., Xention, Oxyrane Belgium NV and Forbion European Acquisition Corporation (Nasdaq: FRBN). Mr. Slootweg was responsible for several substantial exits: Forbion's major position in Argenx SE (Nasdaq: ARGX), Dezima's acquisition by Amgen in 2015 for up to $1.55 billion and the sale of Biovex Group, Inc. to Amgen in 2011 for up to $1 billion. Mr. Slootweg has previously served on the boards of Pulmagen Therapeutics, Fovea Pharmaceuticals SA (sold to Sanofi-aventis in 2009), uniQure N.V. (IPO on Nasdaq in 2014), Argenta Limited (sold to Galapagos NV in 2010), Alantos Pharmaceuticals, Inc. (sold to Amgen in 2007), Impella CardioSystems AG (sold to Abiomed Inc. in 2005), Pieris Pharmaceuticals, Inc. (IPO on Nasdaq in 2015). Before co-founding Forbion, Mr. Slootweg was an investment director at ABN AMRO Capital Life Sciences. Mr. Slootweg holds degrees in business and financial economics from the Free University of Amsterdam and business administration from Nijenrode University, The Netherlands.
- John W. Smither
-
John W. Smither自2019年5月起担任Arcutis Biotherapeutics, Inc.首席财务官。Smither先生此前曾于2016年1月至2017年3月担任Sienna Biopharmaceuticals，Inc.的首席财务官，并于2018年4月至2019年4月再次担任该职务。2017年10月至2018年3月，他在Kite Pharma与吉利德科学公司整合期间担任临时首席财务官，在此之前，于2016年1月至2017年7月在Unity Biotechnology，Inc.担任首席财务官。更早之前，他曾于2007年11月在Kythera生物制药，Inc.担任首席财务官，直到该公司于2015年10月被Allergan plc收购。1998年至2007年，Smither先生曾在安进公司担任多个职务，包括公司会计主管、安进欧洲分部财务和行政副总裁以及内部审计主管。在加入安进之前，他曾在公共会计师事务所Ernst & Young LLP担任审计合伙人，随后在Ernst & Young担任多家早期公司的首席财务官。Smither先生目前在Achaogen, Inc.的董事会任职。此前，Smither先生曾在Principia Biopharma Inc.生物制药公司的董事会任职。他曾获得洛杉矶加利福尼亚州立大学工商管理学士学位。Smither先生是一名非在职注册会计师，是美国注册会计师协会、加州注册会计师协会和国际财务主管协会的成员。
John W. Smither has served as Arcutis Biotherapeutics, Inc. Chief Financial Officer since May 2019. Mr. Smither previously served as Chief Financial Officer for Sienna Biopharmaceuticals, Inc. from January 2016 to March 2017 and again from April 2018 to April 2019. From October 2017 to March 2018 he was interim Chief Financial Officer for Kite Pharma during its integration with Gilead Sciences, Inc., and prior to that, was Chief Financial Officer at Unity Biotechnology, Inc. from January 2016 to July 2017. Earlier, he served as Chief Financial Officer of Kythera Biopharmaceuticals, Inc. from November 2007 until it was acquired by Allergan plc in October 2015. From 1998 to 2007 Mr. Smither held various positions at Amgen Inc., including head of corporate accounting, vice president of finance and administration for Amgen's European Division and head of internal audit. Prior to joining Amgen, he served as audit partner at Ernst & Young LLP, a public accounting firm, and following his time at Ernst & Young served as Chief Financial Officer of several early stage companies. Mr. Smither currently serves on the board of directors of Achaogen, Inc. Previously, Mr. Smither served on the board of directors of Principia Biopharma Inc. He received a B.S. in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant inactive and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and Financial Executives International. - John W. Smither自2019年5月起担任Arcutis Biotherapeutics, Inc.首席财务官。Smither先生此前曾于2016年1月至2017年3月担任Sienna Biopharmaceuticals，Inc.的首席财务官，并于2018年4月至2019年4月再次担任该职务。2017年10月至2018年3月，他在Kite Pharma与吉利德科学公司整合期间担任临时首席财务官，在此之前，于2016年1月至2017年7月在Unity Biotechnology，Inc.担任首席财务官。更早之前，他曾于2007年11月在Kythera生物制药，Inc.担任首席财务官，直到该公司于2015年10月被Allergan plc收购。1998年至2007年，Smither先生曾在安进公司担任多个职务，包括公司会计主管、安进欧洲分部财务和行政副总裁以及内部审计主管。在加入安进之前，他曾在公共会计师事务所Ernst & Young LLP担任审计合伙人，随后在Ernst & Young担任多家早期公司的首席财务官。Smither先生目前在Achaogen, Inc.的董事会任职。此前，Smither先生曾在Principia Biopharma Inc.生物制药公司的董事会任职。他曾获得洛杉矶加利福尼亚州立大学工商管理学士学位。Smither先生是一名非在职注册会计师，是美国注册会计师协会、加州注册会计师协会和国际财务主管协会的成员。
- John W. Smither has served as Arcutis Biotherapeutics, Inc. Chief Financial Officer since May 2019. Mr. Smither previously served as Chief Financial Officer for Sienna Biopharmaceuticals, Inc. from January 2016 to March 2017 and again from April 2018 to April 2019. From October 2017 to March 2018 he was interim Chief Financial Officer for Kite Pharma during its integration with Gilead Sciences, Inc., and prior to that, was Chief Financial Officer at Unity Biotechnology, Inc. from January 2016 to July 2017. Earlier, he served as Chief Financial Officer of Kythera Biopharmaceuticals, Inc. from November 2007 until it was acquired by Allergan plc in October 2015. From 1998 to 2007 Mr. Smither held various positions at Amgen Inc., including head of corporate accounting, vice president of finance and administration for Amgen's European Division and head of internal audit. Prior to joining Amgen, he served as audit partner at Ernst & Young LLP, a public accounting firm, and following his time at Ernst & Young served as Chief Financial Officer of several early stage companies. Mr. Smither currently serves on the board of directors of Achaogen, Inc. Previously, Mr. Smither served on the board of directors of Principia Biopharma Inc. He received a B.S. in Business Administration from California State University, Los Angeles. Mr. Smither is a Certified Public Accountant inactive and a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants and Financial Executives International.
高管简历
中英对照 | 中文 | 英文- Michael Davidson
Michael Davidson自2021年1月起担任董事会成员。戴维森博士是芝加哥大学的医学教授和脂质诊所主任。他还担任New Amsterdam Pharma的首席执行官。戴维森博士是脂类学领域的领先专家。他进行了1000多项临床试验，发表了350多篇医学期刊文章，并撰写了三本有关脂类学的书籍。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和欧米茄-3脂肪酸的广泛研究。Davidson博士创立了芝加哥临床研究中心，该中心成为美国最大的研究站点，并于1996年被Pharmaceutical产品开发收购。此外，他于2008年创立了Omthera Pharmaceuticals，该公司于2013年被阿斯利康（AstraZeneca）以4.4亿美元收购，最近，他担任Corvidia Therapeutics的创始首席执行官/CSO，该公司于2020年被Novo Nordisk以高达21亿美元的价格收购。Davidson博士获得了内科，心脏病学和临床脂类学的董事会认证。2010年至2011年，他担任美国国家血脂协会主席，被美国糖尿病协会评为过去15年来美国最好的医生之一，并于2010年被评为年度之父。他也是纳斯达克上市的Caladrius Bioscience的董事会成员。
Michael Davidson,was appointed as Newamsterdam Pharma Company N.V. Chief Executive Officer and executive director in November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from August 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co-founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX) and Silence Therapeutics plc (Nasdaq: SLN). Dr. Davidson also serves on the boards of two private biotechnology companies, Sonothera and NanoPhoria Bioscience. Dr. Davidson received his B.A. and M.S. from Northwestern University and his M.D. from The Ohio State University School of Medicine.- Michael Davidson自2021年1月起担任董事会成员。戴维森博士是芝加哥大学的医学教授和脂质诊所主任。他还担任New Amsterdam Pharma的首席执行官。戴维森博士是脂类学领域的领先专家。他进行了1000多项临床试验，发表了350多篇医学期刊文章，并撰写了三本有关脂类学的书籍。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和欧米茄-3脂肪酸的广泛研究。Davidson博士创立了芝加哥临床研究中心，该中心成为美国最大的研究站点，并于1996年被Pharmaceutical产品开发收购。此外，他于2008年创立了Omthera Pharmaceuticals，该公司于2013年被阿斯利康（AstraZeneca）以4.4亿美元收购，最近，他担任Corvidia Therapeutics的创始首席执行官/CSO，该公司于2020年被Novo Nordisk以高达21亿美元的价格收购。Davidson博士获得了内科，心脏病学和临床脂类学的董事会认证。2010年至2011年，他担任美国国家血脂协会主席，被美国糖尿病协会评为过去15年来美国最好的医生之一，并于2010年被评为年度之父。他也是纳斯达克上市的Caladrius Bioscience的董事会成员。
- Michael Davidson,was appointed as Newamsterdam Pharma Company N.V. Chief Executive Officer and executive director in November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from August 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co-founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX) and Silence Therapeutics plc (Nasdaq: SLN). Dr. Davidson also serves on the boards of two private biotechnology companies, Sonothera and NanoPhoria Bioscience. Dr. Davidson received his B.A. and M.S. from Northwestern University and his M.D. from The Ohio State University School of Medicine.
- Michael Davidson
Michael Davidson，于2022年11月被任命为Newamsterdam Pharma Company N.V.首席执行官兼执行董事。Davidson博士曾于2020年8月至2022年11月担任NewAmsterdam Pharma的首席执行官和执行董事。在加入NewAmsterdam Pharma之前，Davidson博士于2016年1月至2018年4月期间担任Corvidia Therapeutics，Inc.的创始人兼首席执行官，并于2018年4月至2020年7月期间担任首席科学/医疗官，当时Corvidia被Novo Nordisk A/S以高达21亿美元的价格收购。戴维森博士是脂质学领域的领先专家，过去15年被评为美国最佳医生，目前也是芝加哥大学的医学教授和脂质诊所主任。戴维森博士于2008年与他人共同创立并担任Omthera Pharmaceuticals，Inc.的首席医疗官，该公司后于2013年被阿斯利康制药公司以高达4.43亿美元的价格收购。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和omega-3脂肪酸的广泛研究。Davidson博士在内科、心脏病学和临床脂质学领域获得董事会认证，并于2010年至2011年担任美国国家脂质协会主席。Davidson博士目前在Tenax Therapeutics, Inc.（纳斯达克：TENX）和Silence Therapeutics plc（纳斯达克：SLN）的董事会任职。戴维森博士还在两家私营生物技术公司Sonothera和NanoPhoria Bioscience的董事会任职。Davidson博士获得了西北大学的学士和硕士学位，并获得了俄亥俄州立大学医学院的医学博士学位。
Michael Davidson,was appointed as Newamsterdam Pharma Company N.V. Chief Executive Officer and executive director in November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from August 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co-founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX) and Silence Therapeutics plc (Nasdaq: SLN). Dr. Davidson also serves on the boards of two private biotechnology companies, Sonothera and NanoPhoria Bioscience. Dr. Davidson received his B.A. and M.S. from Northwestern University and his M.D. from The Ohio State University School of Medicine.- Michael Davidson，于2022年11月被任命为Newamsterdam Pharma Company N.V.首席执行官兼执行董事。Davidson博士曾于2020年8月至2022年11月担任NewAmsterdam Pharma的首席执行官和执行董事。在加入NewAmsterdam Pharma之前，Davidson博士于2016年1月至2018年4月期间担任Corvidia Therapeutics，Inc.的创始人兼首席执行官，并于2018年4月至2020年7月期间担任首席科学/医疗官，当时Corvidia被Novo Nordisk A/S以高达21亿美元的价格收购。戴维森博士是脂质学领域的领先专家，过去15年被评为美国最佳医生，目前也是芝加哥大学的医学教授和脂质诊所主任。戴维森博士于2008年与他人共同创立并担任Omthera Pharmaceuticals，Inc.的首席医疗官，该公司后于2013年被阿斯利康制药公司以高达4.43亿美元的价格收购。他的研究背景包括药物和营养临床试验，包括对他汀类药物、新型降脂药物和omega-3脂肪酸的广泛研究。Davidson博士在内科、心脏病学和临床脂质学领域获得董事会认证，并于2010年至2011年担任美国国家脂质协会主席。Davidson博士目前在Tenax Therapeutics, Inc.（纳斯达克：TENX）和Silence Therapeutics plc（纳斯达克：SLN）的董事会任职。戴维森博士还在两家私营生物技术公司Sonothera和NanoPhoria Bioscience的董事会任职。Davidson博士获得了西北大学的学士和硕士学位，并获得了俄亥俄州立大学医学院的医学博士学位。
- Michael Davidson,was appointed as Newamsterdam Pharma Company N.V. Chief Executive Officer and executive director in November 2022. Dr. Davidson served NewAmsterdam Pharma as its Chief Executive Officer and an executive director from August 2020 to November 2022. Prior to joining NewAmsterdam Pharma, Dr. Davidson was the founder and Chief Executive Officer of Corvidia Therapeutics, Inc. from January 2016 until April 2018 and the Chief Science/Medical Officer from April 2018 until July 2020, when Corvidia was acquired by Novo Nordisk A/S for up to $2.1 billion. Dr. Davidson, who is a leading expert in the field of lipidology and was named in The Best Doctors in America for the past 15 years, is also currently a professor of medicine and director of the lipid clinic at the University of Chicago. Dr. Davidson co-founded and served as the Chief Medical Officer of Omthera Pharmaceuticals, Inc. in 2008, which was later acquired by AstraZeneca Pharmaceuticals in 2013 for up to $443 million. His research background encompasses both pharmaceutical and nutritional clinical trials including extensive research on statins, novel lipid-lowering drugs, and omega-3 fatty acids. Dr. Davidson is board-certified in internal medicine, cardiology, and clinical lipidology and served as President of the National Lipid Association from 2010 to 2011. Dr. Davidson currently serves on the board of directors of Tenax Therapeutics, Inc. (Nasdaq: TENX) and Silence Therapeutics plc (Nasdaq: SLN). Dr. Davidson also serves on the boards of two private biotechnology companies, Sonothera and NanoPhoria Bioscience. Dr. Davidson received his B.A. and M.S. from Northwestern University and his M.D. from The Ohio State University School of Medicine.
- John Kastelein
John Kastelein，于2022年11月被任命为Newamsterdam Pharma Company N.V.首席科学官和非执行董事。Kastelein博士于2020年共同创立了NewAmsterdam Pharma，于2020年1月1日至2022年11月期间担任其首席科学官和执行董事。Kastelein博士还自2013年1月起担任Vascular Research Network Inc.（“VRN”）的首席执行官，并自2018年1月起担任Staten Biotechnology B.V.的首席医疗官。Kastelein博士还担任名誉医学教授，并曾担任阿姆斯特丹大学学术医学中心血管医学系主任。他在荷兰动脉粥样硬化学会顾问委员会任职。2011年，他因在基因治疗领域的研究获得了ZonMW珍珠。Kastelein博士还担任North Sea Therapeutics Inc.、VRN和Oxitope Pharma Inc.的董事会成员。Kastelein博士还担任多家生物技术和制药公司的顾问。Kastelein博士获得阿姆斯特丹大学医学博士学位（荣誉），在阿姆斯特丹大学学术医学中心接受内科培训，在温哥华的不列颠哥伦比亚大学接受脂质学和分子生物学培训。Kastelein博士于1997年在《新英格兰医学杂志》上发表了他关于CETP抑制的首个临床研究。
John Kastelein,was appointed as Newamsterdam Pharma Company N.V. Chief Scientific Officer and non-executive director in November 2022. Dr. Kastelein co-founded NewAmsterdam Pharma in 2020 served as its Chief Scientific Officer and an executive director from January 1, 2020 to November 2022. Dr. Kastelein has also served as the chief executive officer of Vascular Research Network Inc. ("VRN") since January 2013 and as the Chief Medical Officer of Staten Biotechnology B.V. since January 2018. Dr. Kastelein also serves as emeritus professor of medicine and was the chair of the department of vascular medicine at the Academic Medical Center of the University of Amsterdam. He serves on the advisory board of the Dutch Atherosclerosis Society. In 2011 he received the ZonMw Pearl for his research in the field of gene therapy. Dr. Kastelein also serves on the board of directors of North Sea Therapeutics Inc., VRN and Oxitope Pharma Inc. Dr. Kastelein also serves as an advisor to a number of biotech and pharmaceutical companies. Dr. Kastelein was awarded a doctorate in medicine (with honors) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. Dr. Kastelein published his first clinical research on CETP-inhibition in the New England Journal of Medicine in 1997.- John Kastelein，于2022年11月被任命为Newamsterdam Pharma Company N.V.首席科学官和非执行董事。Kastelein博士于2020年共同创立了NewAmsterdam Pharma，于2020年1月1日至2022年11月期间担任其首席科学官和执行董事。Kastelein博士还自2013年1月起担任Vascular Research Network Inc.（“VRN”）的首席执行官，并自2018年1月起担任Staten Biotechnology B.V.的首席医疗官。Kastelein博士还担任名誉医学教授，并曾担任阿姆斯特丹大学学术医学中心血管医学系主任。他在荷兰动脉粥样硬化学会顾问委员会任职。2011年，他因在基因治疗领域的研究获得了ZonMW珍珠。Kastelein博士还担任North Sea Therapeutics Inc.、VRN和Oxitope Pharma Inc.的董事会成员。Kastelein博士还担任多家生物技术和制药公司的顾问。Kastelein博士获得阿姆斯特丹大学医学博士学位（荣誉），在阿姆斯特丹大学学术医学中心接受内科培训，在温哥华的不列颠哥伦比亚大学接受脂质学和分子生物学培训。Kastelein博士于1997年在《新英格兰医学杂志》上发表了他关于CETP抑制的首个临床研究。
- John Kastelein,was appointed as Newamsterdam Pharma Company N.V. Chief Scientific Officer and non-executive director in November 2022. Dr. Kastelein co-founded NewAmsterdam Pharma in 2020 served as its Chief Scientific Officer and an executive director from January 1, 2020 to November 2022. Dr. Kastelein has also served as the chief executive officer of Vascular Research Network Inc. ("VRN") since January 2013 and as the Chief Medical Officer of Staten Biotechnology B.V. since January 2018. Dr. Kastelein also serves as emeritus professor of medicine and was the chair of the department of vascular medicine at the Academic Medical Center of the University of Amsterdam. He serves on the advisory board of the Dutch Atherosclerosis Society. In 2011 he received the ZonMw Pearl for his research in the field of gene therapy. Dr. Kastelein also serves on the board of directors of North Sea Therapeutics Inc., VRN and Oxitope Pharma Inc. Dr. Kastelein also serves as an advisor to a number of biotech and pharmaceutical companies. Dr. Kastelein was awarded a doctorate in medicine (with honors) from the University of Amsterdam, trained in internal medicine at the Academic Medical Center of the University of Amsterdam, and trained in lipidology and molecular biology at the University of British Columbia in Vancouver. Dr. Kastelein published his first clinical research on CETP-inhibition in the New England Journal of Medicine in 1997.
- Marc Ditmarsch
Marc Ditmarsch，于2020年1月加入NewAmsterdam Pharma，担任临床与运营副总裁，并于2022年8月晋升为首席开发官。在加入NewAmsterdam Pharma之前，Ditmarsch博士在2019年至2020年期间担任Gadeta Biotechnology的临床开发和运营独立顾问。从2016年到2019年，Ditmarsch博士在阿斯利康担任国家医疗主任，并从2014年到2016年在全球药物开发组织担任全球产品副总裁。Ditmarsch博士此前曾在F. Hoffmann-La Roche AG工作，并担任血管和急诊医学住院外科医生。Ditmarsch博士获得了阿姆斯特丹自由大学医学院的医学博士学位。
Marc Ditmarsch,joined NewAmsterdam Pharma in January 2020 as its Vice President of Clinical & Operations and was promoted to Chief Development Officer in August 2022. Prior to joining NewAmsterdam Pharma, Dr. Ditmarsch served as an independent consultant for clinical development and operations at Gadeta Biotechnology from 2019 until 2020. From 2016 until 2019, Dr. Ditmarsch served as a country medical director at AstraZeneca and as global product vice president in the global medicines development organization from 2014 until 2016. Dr. Ditmarsch previously worked at F. Hoffmann-La Roche AG and as a vascular and emergency medicine resident surgeon. Dr. Ditmarsch received his M.D. from the faculty of medicine at the Free University in Amsterdam.- Marc Ditmarsch，于2020年1月加入NewAmsterdam Pharma，担任临床与运营副总裁，并于2022年8月晋升为首席开发官。在加入NewAmsterdam Pharma之前，Ditmarsch博士在2019年至2020年期间担任Gadeta Biotechnology的临床开发和运营独立顾问。从2016年到2019年，Ditmarsch博士在阿斯利康担任国家医疗主任，并从2014年到2016年在全球药物开发组织担任全球产品副总裁。Ditmarsch博士此前曾在F. Hoffmann-La Roche AG工作，并担任血管和急诊医学住院外科医生。Ditmarsch博士获得了阿姆斯特丹自由大学医学院的医学博士学位。
- Marc Ditmarsch,joined NewAmsterdam Pharma in January 2020 as its Vice President of Clinical & Operations and was promoted to Chief Development Officer in August 2022. Prior to joining NewAmsterdam Pharma, Dr. Ditmarsch served as an independent consultant for clinical development and operations at Gadeta Biotechnology from 2019 until 2020. From 2016 until 2019, Dr. Ditmarsch served as a country medical director at AstraZeneca and as global product vice president in the global medicines development organization from 2014 until 2016. Dr. Ditmarsch previously worked at F. Hoffmann-La Roche AG and as a vascular and emergency medicine resident surgeon. Dr. Ditmarsch received his M.D. from the faculty of medicine at the Free University in Amsterdam.
- Douglas Kling
Douglas Kling，于2021年3月加入NewAmsterdam Pharma，担任首席运营官。在加入NewAmsterdam Pharma之前，Kling先生于2017年12月至2021年2月期间担任Corvidia Therapeutics，Inc.临床开发高级副总裁。从2015年3月到2017年11月，Kling先生担任Matina BioPharma Holdings，Inc.临床开发高级副总裁。Kling先生获得了杜克大学的学士学位和罗格斯商学院的工商管理硕士学位。
Douglas Kling,joined NewAmsterdam Pharma in March 2021 as its Chief Operating Officer. Prior to joining NewAmsterdam Pharma, Mr. Kling served as the Senior Vice President of Clinical Development at Corvidia Therapeutics, Inc. from December 2017 until February 2021. From March 2015 until November 2017, Mr. Kling served as the Senior Vice President, Clinical Development at Matina BioPharma Holdings, Inc. Mr. Kling earned a B.S. from Duke University and an M.B.A. from Rutgers Business School.- Douglas Kling，于2021年3月加入NewAmsterdam Pharma，担任首席运营官。在加入NewAmsterdam Pharma之前，Kling先生于2017年12月至2021年2月期间担任Corvidia Therapeutics，Inc.临床开发高级副总裁。从2015年3月到2017年11月，Kling先生担任Matina BioPharma Holdings，Inc.临床开发高级副总裁。Kling先生获得了杜克大学的学士学位和罗格斯商学院的工商管理硕士学位。
- Douglas Kling,joined NewAmsterdam Pharma in March 2021 as its Chief Operating Officer. Prior to joining NewAmsterdam Pharma, Mr. Kling served as the Senior Vice President of Clinical Development at Corvidia Therapeutics, Inc. from December 2017 until February 2021. From March 2015 until November 2017, Mr. Kling served as the Senior Vice President, Clinical Development at Matina BioPharma Holdings, Inc. Mr. Kling earned a B.S. from Duke University and an M.B.A. from Rutgers Business School.
- Louise Kooij
Louise Kooij，于2023年3月被任命为公司临时首席财务官。Kooij女士于2020年5月加入公司担任公司首席财务官。2023年1月，Kooij女士被任命为公司首席会计官，并在该职位上任职至2023年3月。Kooij女士此前在跨国生物技术公司Genzyme Europe B.V.担任过14年的各种财务职务。自2020年5月以来，Kooij女士还担任独立顾问，担任其他私营生物技术初创企业的首席财务官。2016年1月至2018年4月，Kooij女士领导Genzyme在欧洲的业务运营团队，并从2018年4月至2020年5月，担任Genzyme在中欧和东欧的罕见病部门负责人。Kooij女士获得了Nyenrode商业大学的硕士学位和Hogeschool Markus Verbeek的审计学位。
Louise Kooij,was appointed as the Company's Interim Chief Financial Officer in March 2023. Ms. Kooij joined the Company as its Chief Financial Officer in May 2020. In January 2023, Ms. Kooij was appointed as the Company's Chief Accounting Officer and and served in that role until March 2023. Ms. Kooij previously spent 14 years working in various finance roles at Genzyme Europe B.V., a multinational biotechnology company. Since May 2020, Ms. Kooij has also served as an independent consultant in the role of chief financial officer to other private biotechnology start ups. From January 2016 to April 2018, Ms. Kooij led Genzyme's business operations team in Europe and from April 2018 until May 2020, served as the head of Genzyme's rare disease unit in central and eastern Europe. Ms. Kooij received a master's degree from Nyenrode Business University and her auditing degree from Hogeschool Markus Verbeek.- Louise Kooij，于2023年3月被任命为公司临时首席财务官。Kooij女士于2020年5月加入公司担任公司首席财务官。2023年1月，Kooij女士被任命为公司首席会计官，并在该职位上任职至2023年3月。Kooij女士此前在跨国生物技术公司Genzyme Europe B.V.担任过14年的各种财务职务。自2020年5月以来，Kooij女士还担任独立顾问，担任其他私营生物技术初创企业的首席财务官。2016年1月至2018年4月，Kooij女士领导Genzyme在欧洲的业务运营团队，并从2018年4月至2020年5月，担任Genzyme在中欧和东欧的罕见病部门负责人。Kooij女士获得了Nyenrode商业大学的硕士学位和Hogeschool Markus Verbeek的审计学位。
- Louise Kooij,was appointed as the Company's Interim Chief Financial Officer in March 2023. Ms. Kooij joined the Company as its Chief Financial Officer in May 2020. In January 2023, Ms. Kooij was appointed as the Company's Chief Accounting Officer and and served in that role until March 2023. Ms. Kooij previously spent 14 years working in various finance roles at Genzyme Europe B.V., a multinational biotechnology company. Since May 2020, Ms. Kooij has also served as an independent consultant in the role of chief financial officer to other private biotechnology start ups. From January 2016 to April 2018, Ms. Kooij led Genzyme's business operations team in Europe and from April 2018 until May 2020, served as the head of Genzyme's rare disease unit in central and eastern Europe. Ms. Kooij received a master's degree from Nyenrode Business University and her auditing degree from Hogeschool Markus Verbeek.